206 related articles for article (PubMed ID: 22802682)
1. Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.
Meng Y; Liu S; Li J; Meng Y; Zhao X
Int J Nanomedicine; 2012; 7():3133-42. PubMed ID: 22802682
[TBL] [Abstract][Full Text] [Related]
2. Mono-PEGylation of Alpha-MMC and MAP30 from Momordica charantia L.: Production, Identification and Anti-Tumor Activity.
Sun Y; Sun F; Li J; Wu M; Fan X; Meng Y; Meng Y
Molecules; 2016 Oct; 21(11):. PubMed ID: 27809255
[TBL] [Abstract][Full Text] [Related]
3. A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.
Meng Y; Lin S; Liu S; Fan X; Li G; Meng Y
PLoS One; 2014; 9(7):e101998. PubMed ID: 25003606
[TBL] [Abstract][Full Text] [Related]
4. PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of α-momorcharin in vivo.
Zheng JC; Lei N; He QC; Hu W; Jin JG; Meng Y; Deng NH; Meng YF; Zhang CJ; Shen FB
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):866-73. PubMed ID: 22439816
[TBL] [Abstract][Full Text] [Related]
5. PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential.
Bian X; Shen F; Chen Y; Wang B; Deng M; Meng Y
Biotechnol Lett; 2010 Jul; 32(7):883-90. PubMed ID: 20238144
[TBL] [Abstract][Full Text] [Related]
6. Α-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells.
Fan X; He L; Meng Y; Li G; Li L; Meng Y
Mol Med Rep; 2015 May; 11(5):3553-8. PubMed ID: 25573293
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol.
Li M; Chen Y; Liu Z; Shen F; Bian X; Meng Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):792-9. PubMed ID: 19727528
[TBL] [Abstract][Full Text] [Related]
8. Immunoaffinity purification of α-momorcharin from bitter melon seeds (Momordica charantia).
Yao X; Li J; Deng N; Wang S; Meng Y; Shen F
J Sep Sci; 2011 Nov; 34(21):3092-8. PubMed ID: 21994203
[TBL] [Abstract][Full Text] [Related]
9. Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy.
Puri M; Kaur I; Kanwar RK; Gupta RC; Chauhan A; Kanwar JR
Curr Mol Med; 2009 Dec; 9(9):1080-94. PubMed ID: 19747115
[TBL] [Abstract][Full Text] [Related]
10. Ribosome-inactivating Protein MAP30 Isolated from
Zhou Y; Yang D; Qiang Z; Meng Y; Li R; Fan X; Zhao W; Meng Y
Recent Pat Anticancer Drug Discov; 2024; 19(2):223-232. PubMed ID: 36330636
[TBL] [Abstract][Full Text] [Related]
11. Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant
Chen YJ; Zhu JQ; Fu XQ; Su T; Li T; Guo H; Zhu PL; Lee SK; Yu H; Tse AK; Yu ZL
Toxins (Basel); 2019 Nov; 11(12):. PubMed ID: 31779275
[TBL] [Abstract][Full Text] [Related]
12. Alpha-momorcharin possessing high immunogenicity, immunotoxicity and hepatotoxicity in SD rats.
Meng Y; Liu B; Lei N; Zheng J; He Q; Li D; Zhao X; Shen F
J Ethnopharmacol; 2012 Jan; 139(2):590-8. PubMed ID: 22172326
[TBL] [Abstract][Full Text] [Related]
13. PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo.
Deng NH; Wang L; He QC; Zheng JC; Meng Y; Meng YF; Zhang CJ; Shen FB
Drug Deliv; 2016; 23(1):95-100. PubMed ID: 24786488
[TBL] [Abstract][Full Text] [Related]
14. Chemosynthesis and characterization of site-specific N-terminally PEGylated Alpha-momorcharin as apotential agent.
Sun W; Sun J; Zhang H; Meng Y; Li L; Li G; Zhang X; Meng Y
Sci Rep; 2018 Dec; 8(1):17729. PubMed ID: 30531997
[TBL] [Abstract][Full Text] [Related]
15. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
Chen WW; Zhang HR; Huang ZG; Zhou ZY; Lou QW; Jiang XY; Zhu ZH
Protein Expr Purif; 2021 Sep; 185():105893. PubMed ID: 33933613
[TBL] [Abstract][Full Text] [Related]
16. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
17. MAP30 and luffin-α: Novel ribosome-inactivating proteins induce plant systemic resistance against plant viruses.
Wei Z; Yang L; Liu W; Xu X; Ran M; Jin Y; Sun X
Pestic Biochem Physiol; 2023 Apr; 191():105342. PubMed ID: 36963924
[TBL] [Abstract][Full Text] [Related]
18. Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity.
Lv Q; Yang XZ; Fu LY; Lu YT; Lu YH; Zhao J; Wang FJ
Protein Expr Purif; 2015 Jul; 111():9-17. PubMed ID: 25797209
[TBL] [Abstract][Full Text] [Related]
19. Alpha-momorcharin (α-MMC) exerts effective anti-human breast tumor activities but has a narrow therapeutic window in vivo.
Cao D; Sun Y; Wang L; He Q; Zheng J; Deng F; Deng S; Chang S; Yu X; Li M; Meng Y; Jin J; Shen F
Fitoterapia; 2015 Jan; 100():139-49. PubMed ID: 25447153
[TBL] [Abstract][Full Text] [Related]
20. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].
Zhang LL; Ding Q; Zhan JB
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 May; 39(3):264-71. PubMed ID: 20544988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
